Waters Stock News

MILFORD, Mass. , May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D.

U.S.-based Waters Corp , which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters.

Waters Corporation's stock remains a "Hold" due to high valuation multiples, despite a 35% increase in stock price and improved business performance. The company reported solid Q1 2025 results, with 3.9% revenue growth and 18% EPS growth, but valuation remains above historical averages. Management is optimistic about future growth, citing opportunities in the Indian market, GLP-1 testing, and p...

Waters Corporation (NYSE:WAT ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Caspar Tudor - Head of Investor Relations Udit Batra - President and Chief Executive Officer Amol Chaubal - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research LLC Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherin...

Waters raised its annual profit forecast on Tuesday, after reporting better-than-expected first quarter results due to higher demand for its medical instruments in Asia and the Americas.

News Summary  Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass. , May 6, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) t...

Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currency Results led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end markets Earnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25 Rai...

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetr...